Search Results 1391-1400 of 17869 for monoclonal antibody

1. Medical Research & Education - Mayo Clinic News Network

   ROCHESTER, Minn. — A new Mayo Clinic study published in the New England Journal of Medicine has uncovered that an off-the-shelf, dual-antibody therapy can ...

2. Clinical trials - Oncology (Medical)

   UP-NEXT is a double-blind, randomized, placebo controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an ...

3. TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study - Mayo Clinic

   Treatment with any monoclonal antibody within 3 months prior to Screening. Identified pre-existing ophthalmic disease that, in the judgment of the ...

4. Burkitt Lymphoma Clinical Trials

   An Open-label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or ...

5. A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) - Mayo Clinic

   Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint inhibitors, other monoclonal antibodies, antibody-drug conjugates ...

6. Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ - Mayo Clinic

   History of severe allergic or anaphylactic reaction to monoclonal antibody therapy. Confirmed diagnosis of progressive multifocal leukoencephalopathy ...

7. A Phase 2, Multicenter, Randomized Study of AP26113 - Mayo Clinic

   Received monoclonal antibodies or had major surgery within 30 days of the first dose of AP26113 (Day 1, Cycle 1). Have been diagnosed with another primary ...

8. A Study of Pembrolizumab Alone as Therapy for Metastatic Triple-Negative Breast Cancer - Mayo Clinic

   Prior anti-cancer monoclonal antibody (mAb) therapy for direct anti-neoplastic treatment within 4 weeks prior to study Day 1; Prior chemotherapy, targeted ...

9. Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52) - Mayo Clinic

   Prior anti-cancer monoclonal antibody (mAb) for direct anti-neoplastic treatment within 4 weeks prior to study Day 1 or who has not recovered from adverse ...

10. mRNA transfection improves CTL response in immunotherapy - Mayo Clinic

    In a 2022 study, Mayo Clinic researchers found that by transfecting cytotoxic CD8+ T cells with mRNA of natural killer cells they can improve response in ...